Title:In vitro and in silico Xanthine Oxidase Inhibitory Activity of Selected Phytochemicals Widely Present in Various Edible Plants
Volume: 23
Issue: 9
Author(s): Arshad Mehmood, Ashfaq Ur Rehman, Muhammad Ishaq, Liang Zhao, Jiayi Li, Muhammad Usman, Lei Zhao*, Abdur Rehman, Oumeddour D. Zad and Chengtao Wang*
Affiliation:
- Beijing Advance Innovation Center for Food Nutrition and Human Health, School of Food and Chemical Technology, China-Canada Joint Laboratory for Food Nutrition and Health, Beijing Technology and Business University (BTBU), Beijing 100048,China
- Beijing Advance Innovation Center for Food Nutrition and Human Health, School of Food and Chemical Technology, China-Canada Joint Laboratory for Food Nutrition and Health, Beijing Technology and Business University (BTBU), Beijing 100048,China
Keywords:
Xanthine oxidase, hyperuricemia, gout, antioxidant activities, phytochemicals, bioactive compounds.
Abstract:
Aim and Objective: The present study was designed to evaluate the xanthine oxidase
(XO) inhibitory and antioxidant activities of 30 bioactive compounds present in edible food plants
for the possible treatment of hyperuricemia.
Materials and Methods: The XO inhibitory, SO and DPPH radical scavenging activities of
selected dietary polyphenols were determined by using colorimetric assays. The molecular docking
analysis was performed to evaluate the insight into inhibitory mode of action of bioactive
compounds against XO.
Results: The results show that apigenin, galangin, kaempferol, quercetin, genistein and resveratrol
potently inhibit XO enzyme among all tested compounds. Flavonoids exhibit higher, anthocyanins
and hydroxycinnamic acids moderate, maslinic acid, ellagic acid, salicylic acid, [6]-gingerol and
flavan-3-ols showed weak XO inhibitory activity. The results of molecular docking study revealed
that these bioactive compounds bind with the active site of XO and occupy the active site which
further prevents the entrance of substrate and results in the inhibition of XO.
Conclusion: Inhibition of XO gives a robust biochemical basis for management of hyperuricemia,
gout and other associated diseases via controlling uric acid synthesis.